Skip to main content
C

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,504 across all filing types
Latest filing 2025-02-28 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement on HKEX regarding a drug candidate receiving Breakthrough Therapy Designation. It does not present financial results (so it is not an Earnings Release or Interim/Annual Report), nor is it a management change, share transaction, dividend, or AGM material. It is a general corporate announcement/filing with no specific category, so it falls under the fallback category "Regulatory Filings (RNS)".
2025-02-28 English
PROFIT WARNING
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Stock Exchange “Profit Warning” announcement under Listing Rule 13.09(2)(a) providing preliminary unaudited full-year results guidance (year ended 31 December 2024) and is not the formal Annual Report, Interim Report, Dividend Notice, or any other structured financial report. It contains regulatory disclosures required by the Exchange but does not include audited financial statements or comprehensive management discussion typical of an Interim/Annual report. There is no specific “profit warning” category in the taxonomy, so it falls under the fallback “Regulatory Filings (RNS).”
2025-02-25 English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement of an exclusive license agreement for a pharmaceutical product. It is not a financial report (Annual, Interim or Earnings), nor a regulatory form (e.g., director dealings, share issuance, dividends, delisting). It does not announce a management change, M&A, or share repurchase. It provides business agreement details and upfront/milestone payments information, which does not constitute a capital financing transaction under our definitions. Therefore, it falls under the fallback category “Regulatory Filings” for general announcements that do not fit other specific categories.
2025-02-19 English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR ENYITAN (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on HKEx regarding the marketing approval of a new drug indication. It does not present financial results, voting information, share issuances, or management changes. It is not a periodic report or investor presentation but a general regulatory-type announcement. Therefore, it falls under the general regulatory announcement category (RNS).
2025-02-10 English
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement on the Hong Kong Exchange about FDA approval to conduct clinical trials for a drug. It is not an annual or interim report, earnings release, board change, dividends notice, share transaction, M&A update, or any other specific category. It does not include a report attachment or filing itself but is a general business/regulatory announcement. Therefore it falls into the fallback category ‘Regulatory Filings’ (RNS).
2025-02-10 English
VOLUNTARY ANNOUNCEMENT - SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement regarding clinical trial approval for the company’s vaccine candidate, published on the Hong Kong Exchange with standard disclaimer language. It is not a financial report, earnings release, dividend notice, board change, or any of the specific categories listed. It does not present financial data or results, nor is it soliciting votes or describing M&A or share transactions. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2025-02-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.